BeiGene, Ltd. (BGNE) PT Raised to $207 at Bernstein SocGen GroupThe analyst said: "In this model update of BeiGene post-earnings, we present a new, integrated B-cell malignancies market model covering all four classes of treatment (chemo and R-CHOP, BTKi, Bcl-2, and BTK degrader) and renew our projections for the three important B-cell malignancies drugs of the company (zanubrutinib, sonrotoclax, and BGB-16673).